Sep 8, 2017

Allergan transfers drug patent to Native American tribe

Allergan struck a unique deal to protect a drug patent. Photo: Richard Drew / AP

Drug maker Allergan has forged a deal to save the patent protection for one of its drugs by transferring the patents to the Saint Regis Mohawk Tribe in New York, a sovereign entity that is immune from patent reviews.

The numbers: Allergan will give the tribe its patents for Restasis — an eye care drug with $1.5 billion of worldwide sales last year — and pay the tribe $13.75 million upfront and $15 million annually in royalties.

Why it matters: Allergan made it clear the Saint Regis Mohawk Tribe approached the company. But the deal raises two issues: the extent pharmaceutical companies are willing to go to save lucrative patents of their brand-name drugs; and the poor financial shape of America's native tribes that makes these kinds of deals attractive.

Go deeper

Coronavirus kills 2 Diamond Princess passengers and South Korea sees first death

Data: The Center for Systems Science and Engineering at Johns Hopkins, the CDC, and China's Health Ministry. U.S. numbers include Americans extracted from Princess Cruise ship.

Two elderly Diamond Princess passengers have been killed by the novel coronavirus — the first deaths confirmed among the more than 600 infected aboard the cruise ship. South Korea also announced its first death Thursday.

The big picture: COVID-19 has now killed more than 2,200 people and infected over 75,465 others, mostly in mainland China, where the National Health Commission announced 118 new deaths since Thursday.

Go deeperArrowUpdated 48 mins ago - Health

SoftBank to cut its stake to get T-Mobile's Sprint deal done

Illustration: Rebecca Zisser/Axios

T-Mobile and Sprint announced a revised merger agreement that will see SoftBank getting a smaller share of the combined company, while most shareholders will receive the previously agreed upon exchange rate. The companies said they hope to get the deal as early as April 1.

Why it matters: The amended deal reflects the decline in Sprint's business, while leaving most shareholders' stake intact and removing another hurdle to the deal's closure.